Benign prostatic hyperplasia
Conditions
Interventions
Novel surgical treament techniques group:Novel surgical treatment techniques category 1
TURP group:TURP
New technology treatment group:Novel surgical treatment techniques category 2
Experimental group:Life proactive intervention programs
Control group:Maintain the old lifestyle
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Novel surgical techniques studies: (1) Men, aged 50 to 85 years; (2) Patients with BPH scheduled for surgical treatment; (3) IPSS score of 8 to 35; (4) Prostate volume >= 30 ml; (5) Maximum urinary flow rate (Qmax) <=15 ml/sec; (6) Able to complete the relevant scale score under medical supervision; (7) Voluntary participation and signed informed consent form. 2.Active prevention and control studies: (1) Elderly male patients who meet the criteria for metabolic syndrome (metabolic syndrome using the diagnostic criteria recommended by the Chinese Medical Association's Diabetes Mellitus Branch); (2) Able to complete the relevant scale scores under medical supervision; (3) Voluntary participation and signed informed consent form.
Exclusion criteria
Exclusion criteria: 1.Novel surgical techniques studies: (1) Patients with neurogenic cystitis, urethral stricture and inability to pass the cystoscopic sheath after transurethral dilation are diagnosed or suspected of prostate and bladder cancer; (2) Patients with severe cardiovascular and cerebrovascular disease, severe respiratory disease and severe liver and kidney dysfunction; (3) Patients who participated in other clinical trials within three months prior to enrollment; (4) Other conditions that the investigator considers inappropriate for enrollment. 2.Active prevention and control studies: (1) Patients with psychiatric disorders; (2) Patients with confirmed or suspected prostate cancer or bladder cancer; (3) Patients with severe cardiovascular and cerebrovascular disease, severe respiratory disease and severe liver and kidney dysfunction; (4) Patients who participated in other clinical trials within three months prior to enrolment; (5) Other conditions that the investigator considers inappropriate for enrollment; (6) BPH patients with surgical indications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostatic Symptom Scale;Maximum urinary flow rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Life quality score;Operative time;Removal efficiency;Duration of indwelling urinary catheter;Postoperative bladder irrigation time;Haemoglobin drop;International Index of Erectile Function;Retrograde ejaculation;Prostate-specific antigen;Residual urine;Acute urinary retention;Urinary tract infection; | — |
Countries
China
Contacts
Public ContactSong Tao
Chinese PLA General Hospital
Outcome results
None listed